Aqtual is a biotechnology diagnostics platform that provides healthcare solutions, novel technology, and biochemistry for chronic disease.
Aqtual has raised $31.0M in total funding. The most recent round was Series B. The last funding was announced in July 2025.
Aqtual's investors include Genoa Ventures, Bold Capital Partners, Manta Ray Ventures, Yu Galaxy, BOLD Longevity Growth Fund.
Aqtual is headquartered in Hayward, United States.
Aqtual is a biotechnology diagnostics platform that provides healthcare solutions, novel technology, and biochemistry for chronic disease.
Aqtual is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aqtual — Funding & Investors." VCBacked, July 10, 2025, https://www.vcbacked.co/company/aqtual. Accessed September 14, 2026.
VCBacked. (2025). Aqtual — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/aqtual
{{cite web |title=Aqtual — Funding & Investors |url=https://www.vcbacked.co/company/aqtual |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated